Increase of Serum Interleukin-10 in Intractable Graves' Disease

Thyroid

Volumn 14, Issue 3, 2004, Pages 201-205

  Takeoka, Keiko ^a,b   Watanabe, Mikio ^a   Matsuzuka, Fumio ^c   Miyauchi, Akira ^c   Iwatani, Yoshinori ^a  

^a OSAKA UNIVERSITY GRADUATE SCHOOL OF MEDICINE   (Japan)

^b OSAKA UNIVERSITY HOSPITAL   (Japan)

^c KUMA HOSPITAL   (Japan)

Author keywords

[No Author keywords available]

Indexed keywords

ANTITHYROID AGENT; INTERLEUKIN 10; INTERLEUKIN 4; PROPYLTHIOURACIL; THIAMAZOLE; THYROTROPIN RECEPTOR ANTIBODY;

ARTICLE; AUTOIMMUNE DISEASE; CONCENTRATION (PARAMETERS); CONTROLLED STUDY; DISEASE SEVERITY; ENZYME LINKED IMMUNOSORBENT ASSAY; FEMALE; GRAVES DISEASE; HASHIMOTO DISEASE; HUMAN; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL; REMISSION; SERUM;

ADULT; ANTIBODIES; ANTITHYROID AGENTS; CASE-CONTROL STUDIES; DRUG ADMINISTRATION SCHEDULE; FEMALE; GRAVES DISEASE; HUMANS; INTERLEUKIN-10; INTERLEUKIN-4; MALE; MIDDLE AGED; OSMOLAR CONCENTRATION; RECEPTORS, THYROTROPIN; REMISSION INDUCTION; SEVERITY OF ILLNESS INDEX; THYROIDITIS, AUTOIMMUNE;

EID: 1842429848     PISSN: 10507256     EISSN: None     Source Type: Journal    
DOI: 10.1089/105072504773297876     Document Type: Article

References (24)

1. Davies TF 2000 Pathogenesis of Graves' disease. In: Braverman LE, Utiger RD (eds) The Thyroid: A Fundamental and Clinical Text. Lippincott Williams & Wilkins, Philadelphia, pp. 518-531.
2. Volpe R 2001 The immune system and its role in endocrine function. In: Becker KL (ed). Principles and Practice of Endocrinology and Metabolism. Lippincott Williams & Wilkins, Philadelphia, pp. 1770-1781.
3. + cells and thyroid autoantibodies in disease severity of Hashimoto's disease. Thyroid 12:801-808.
4. Watanabe M, Yamamoto N, Maruoka H, Matsuzuka F, Miyauchi A, Iwatani Y 2003 Relation of CD30 molecules on T-cell subsets to the severity of autoimmune thyroid disease. Thyroid 13:259-263.
5. Nakamoto Y, Niki M, Watanabe M, Iwatani Y 2003 Increase in immunoglobulin G3-secreting cells in intractable Graves' disease. Thyroid 13:325-331.
6. Iwatani Y, Watanabe M 1999 Normal mechanisms for self-tolerance. In: Volpe R (ed). Autoimmune Endocrinopathies. Humana Press, Inc., Totawa, pp. 1-30.
7. Briere F, Servet-Delprat C, Bridon JM, Saint-Remy JM, Banchereau J 1994 Human interleukin 10 induces naive surface immunoglobulin D+ (sIgD+) B cells to secrete IgG1 and IgG3. J Exp Med 179:757-762.
8. Banchereau J 1995 Converging and diverging properties of human interleukin-4 and interleukin-10. Behring Inst Mitt Jun:58-77.
9. Fujieda S, Zhang K, Saxon A 1995 IL-4 plus CD40 monoclonal antibody induces human B cells gamma subclass-specific isotype switch: Switching to gamma 1, gamma 3, and gamma 4, but not gamma 2. J Immunol 155:2318-2328.
10. Fujieda S, Sieling PA, Modlin RL, Saxon A 1998 CD1-restricted T-cells influence IgG subclass and IgE production. J Allergy Clin Immunol 101:545-551.
11. Komorowski J, Jankiewicz J, Robak T, Blasinska-Morawiec M, Stepien H 1998 Cytokines serum levels as the markers of thyroid activation in Graves' disease. Immunol Lett 60:143-148.
12. Huang DR, Zhou YH, Xia SQ, Liu L, Pirskanen R, Lefvert AK 1999 Markers in the promoter region of interleukin-10 (IL-10) gene in myasthenia gravis: Implications of diverse effects of IL-10 in the pathogenesis of the disease. J Neuroimmunol 94:82-87.
13. Lalani I, Bhol K, Ahmed AR 1997 Interleukin-10: Biology, role in inflammation and autoimmunity. Ann Allergy Asthma Immunol 79:469-483.
14. Fujieda S, Saxon A, Zhang K 1996 Direct evidence that gamma 1 and gamma 3 switching in human B cells is interleukin-10 dependent. Mol Immunol 33:1335-1343.
15. Burman KD, Baker JR Jr 1985 Immune mechanisms in Graves' disease. Endocr Rev 6:183-232.
16. Ishida H, Muchamuel T, Sakaguchi S, Andrade S, Menon S, Howard M 1994 Continuous administration of anti-interleukin 10 antibodies delays onset of autoimmunity in NZB/W F1 mice. J Exp Med 179:305-310.
17. Houssiau FA, Lefebvre C, Vanden Berghe M, Lambert M, Devogelaer JP, Renauld JC 1995 Serum interleukin 10 titers in systemic lupus erythematosus reflect disease activity. Lupus 4:393-395.
18. Zhang GX, Xiao BG, Yu LY, van der Meide PH, Link H 2001 Interleukin 10 aggravates experimental autoimmune myasthenia gravis through inducing Th2 and B cell responses to AChR. J Neuroimmunol 113:10-18.
19. de Waal Malefyt R, Yssel H, Roncarolo MG, Spits H, de Vries JE 1992 Interleukin-10. Curr Opin Immunol 4:314-320.
20. Mosmann TR 1994 Properties and functions of interleukin-10. Adv Immunol 56:1-26.
21. Francis T, Burch HB, Cai WY, Lukes Y, Peele M, Carr FE, Wartofsky L, Burman KD 1991 Lymphocytes express thyrotropin receptor-specific mRNA as detected by the PCR technique. Thyroid 1:223-228.
22. Pekonen F, Weintraub BD 1978 Thyrotropin binding to cultured lymphocytes and thyroid cells. Endocrinology 103:1668-1677.
23. Blalock JE, Johnson HM, Smith EM, Torres BA 1984 Enhancement of the in vitro antibody response by thyrotropin. Biochem Biophys Res Commun 125:30-34.
24. Kruger TE, Blalock JE 1986 Cellular requirements for thyrotropin enhancement of in vitro antibody production. J Immunol 137:197-200.